Table 3.
Adverse outcome group n = 13 |
Favorable outcome group n = 29 |
p-value | |
---|---|---|---|
Cerebral oxygen saturation (%) | |||
crSO2 min 2 | 23 (13-34) | 41 (34-48) | 0.008* |
crSO2 min 3 | 27 (16-38) | 45 (37-52) | 0.007* |
crSO2 min 4 | 31 (21-42) | 49 (42-56) | 0.006* |
crSO2 min 5 | 42 (32-53) | 54 (47-61) | 0.072 |
crSO2 min 6 | 50 (40-60) | 59 (53-66) | 0.145 |
crSO2 min 7 | 51 (41-61) | 65 (58-71) | 0.029* |
crSO2 min 8 | 55 (45-66) | 68 (61-75) | 0.046* |
crSO2 min 9 | 60 (50-70) | 70 (63-77) | 0.118 |
crSO2 min 10 | 59 (48-69) | 73 (66-79) | 0.027* |
crSO2 min 11 | 63 (53-73) | 75 (68-81) | 0.067 |
crSO2 min 12 | 63 (52-73) | 75 (69-82) | 0.043* |
crSO2 min 13 | 61 (50-71) | 74 (67-81) | 0.033* |
crSO2 min 14 | 63 (52-73) | 76 (69-83) | 0.041* |
crSO2 min 15 | 62 (52-73) | 78 (71-85) | 0.017* |
Cerebral fractional oxygen extraction | |||
cFTOE min 2 | 0.545 (0.431-0.659) | 0.380 (0.305-0.455) | 0.018* |
cFTOE min 3 | 0.509 (0.398-0.620) | 0.345 (0.273-0.418) | 0.016* |
cFTOE min 4 | 0.500 (0.392-0.607) | 0.286 (0.215-0.358) | 0.001* |
cFTOE min 5 | 0.421 (0.317-0.525) | 0.286 (0.216-0.356) | 0.035* |
cFTOE min 6 | 0.369 (0.268-0.470) | 0.281 (0.212-0.350) | 0.157 |
cFTOE min 7 | 0.394 (0.292-0.496) | 0.225 (0.157-0.293) | 0.007* |
cFTOE min 8 | 0.373 (0.269-0.477) | 0.212 (0.144-0.280) | 0.011* |
cFTOE min 9 | 0.314 (0.209-0.419) | 0.200 (0.132-0.268) | 0.075 |
cFTOE min 10 | 0.350 (0.242-0.457) | 0.185 (0.117-0.252) | 0.011* |
cFTOE min 11 | 0.309 (0.200-0.417) | 0.175 (0.108-0.242) | 0.040* |
cFTOE min 12 | 0.297 (0.189-0.404) | 0.170 (0.103-0.238) | 0.051 |
cFTOE min 13 | 0.338 (0.231-0.445) | 0.173 (0.104-0.241) | 0.012* |
cFTOE min 14 | 0.313 (0.205-0.420) | 0.161 (0.093-0.230) | 0.021* |
cFTOE min 15 | 0.289(0.181-0.397) | 0.145 (0.076-0.215) | 0.028* |